Whole genome · Physician-read · Kept alive for life
A report is read once. A record is returned to.
The Folio is your genome, read completely and made legible, as the founding page of a record that accretes for life: every new prescription checked against your DNA before the first dose, every lab read against your own ranges instead of the population's, every reclassification medicine makes written in, and your physician's notes in the margin. What you own in year three is worth more than what you received on day one.
A variant in your Folio was reclassified
BRCA1 variant of uncertain significance resolved to likely benign, supported by saturation genome-editing evidence curated into the Atlas. Written into your record; nothing to do.
New prescription, read against your genome
Clopidogrel entered your medication list. Your CYP2C19 *1/*2 status predicts reduced activation. A one-page note reached your prescriber the same hour.
This year's draw, against your own last year
Annual proteomic profile compared to your prior values, not the population's. Two proteins moved outside your personal band; both surfaced for physician review.
Sequence once
One draw. Your whole genome at 30x becomes page one of the record, complete and done for life.
Everything reads against it
New prescriptions, labs, and results are interpreted through your genome, never filed beside it.
The record writes itself
Reclassifications, checks, and physician notes arrive as numbered entries. You return because it changed.
Why the genome anchors everything
Genetics is the one prior in medicine that was set before you were born.
Every other measurement of you is a snapshot that moves with sleep, stress, and season. Your genome was fixed at conception and randomized by nature, which is why it carries causal weight nothing downstream can match: published analyses of drug pipelines find that targets backed by human genetic evidence succeed in the clinic at roughly twice the rate of those without it.1 Medicine already trusts the genome more than any other data type. It just reads it last, at the end of illness, instead of first.
The Folio moves the reading to the front, once, and then makes every later measurement answer to it.
1. Nelson et al., Nature Genetics, 2015, "The support of human genetic evidence for approved drug indications." King, Davis, and Degner, PLOS Genetics, 2019, "Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval." The effect is an estimate and varies across analyses and methods. Roughly twofold, not exactly twofold.
Day one · The founding page
Seven sections, written for an intelligent adult. Labeled with unusual honesty.
Your whole genome, interpreted to clinical standards and physician-reviewed. The italic line on each card is not marketing copy. It is the label we would want if it were our genome, including the two sections most companies oversell and the one the rest of the industry refuses to report.
Identity and ancestry
Deep ancestral composition, haplogroups, and the population structure that determines how the rest of your Folio should be read.
The most engaging section and the least clinically useful. It is the on-ramp, and we treat it as one.
Monogenic risk
High-penetrance findings across the medically actionable gene set, reported with penetrance and family context rather than as a verdict.
Two to four percent of adults carry an actionable finding. This section is why a physician reads your Folio before you do.
Carrier status
Recessive findings across a broad panel, with partner and family implications made explicit.
About one in five adults carries something relevant to reproductive planning. Quiet information with long consequences.
Pharmacogenomics
Drug and gene interactions across the established PGx genes, matched continuously against your live prescription list.
The most durable section in the Folio, because it fires again every time a prescription changes.
Polygenic risk
Common-variant risk across major disease systems, presented as intervals with ancestry caveats and a plain account of what it does not mean.
The weakest evidence in your Folio. We show it as an interval with its caveats attached, or not at all.
Traits and physiology
Metabolism, nutrient handling, exercise response, sleep and sensory traits.
Low clinical weight, high curiosity value, and walled off from the medical sections so the two are never confused.
Resilience
Every clinical pipeline on earth is built to find what is broken and, by design, discards what protects. Yet the most consequential genetics of the last two decades ran the other way: people walking around with a gene switched off and better health because of it. Carriers of broken PCSK9 ran lifelong low cholesterol, and an entire class of drugs was built to copy them. Your Folio reads your genome in both directions and reports the protective findings with the same rigor as the pathogenic ones.
If your genome carries one of these variants, that fact belongs to you first. Should you choose, through a specific, revocable consent, it can also inform the search for medicines that give everyone else what nature gave you. Some genomes carry the outline of a cure. No section of your Folio is shared without your instruction, this one included.
The structure of the record
Layer one is bought once. Everything above it changes. The membership is for what changes.
Foundation
Whole genome at 30x, re-sequenced every two to three years.
The founding page. Re-sequencing is for what your blood acquires with age, not a better reading of what you were born with.
Molecular
Plasma proteomics, NMR metabolomics, clinical chemistry, and plasma banked at every draw.
The dynamic layer, read against layer one to produce your personal reference ranges rather than the population's.
Clinical and behavioral
History, live medication list, family structure, screening record, wearable and glucose windows.
The context that makes the layers below it actionable, and the cheapest source of density between annual draws.
Interpretation
Reinterpretation agents, medication matching, variant-effect curation, the personal range engine, physician annotation.
What the membership is actually for after year one. Agents surface. Physicians decide.
The personal range engine
Your normal is not the population's normal.
Population-scale genetics has mapped how DNA sets the baseline level of thousands of blood proteins, and the maps are public. Because your Folio holds your genome and your bloodwork on the same page, it can say what no panel-testing company can: this value is high for the population but normal for you, so nothing needs to happen. And the more valuable inverse: this value looks fine for the population, but for your genotype it is drifting, and the quiet drift is the signal.
Try the toggle. The same number, read two ways, is the difference between a scare and a signal.
94th percentile. A panel company prints this in red and tells you to worry.
You carry IL6R p.Asp358Ala, which raises this protein constitutionally. Squarely inside your personal band. No action, and no scare.
Why the Folio stays open
Four reasons your record changes without you lifting a finger.
The consumer genetics graveyard is full of reports that were read once, admired, and never opened again. The Folio is engineered around the opposite behavior. Its software agents work continuously and surface what they find for clinical review. Agents surface. Physicians decide. That sentence is both the honest description of the product and the reason it is defensible.
Governance · Structural, not marketing
A promise you can copy is worth nothing. So we made it structure.
The 23andMe bankruptcy put consented genomes in front of buyers no member ever selected. Every company since has promised not to sell your data, which is exactly why the promise alone is worthless. The Folio's governance is built so that keeping the promise does not depend on our intentions, our investors, or our survival.
A binding instrument, not a policy
Member data protections sit in charter-level provisions and a dedicated governance vehicle, not in a privacy policy a future board can amend on a Tuesday.
Technically precluded, not just prohibited
The architecture is built so that re-identification and bulk transfer are prevented by design, and a third party attests to that annually. You do not have to trust the intention, because the capability is absent.
The Atlas is a commons, not an asset
The shared reference library every Folio reads against is opt-in, de-identified, and readable by members. It is never licensed to third parties. No exceptions, at any price.
Banking is consented, specific, and revocable
Plasma banked at your draws is held for future assays you have specifically consented to. Revoke, and the aliquots are destroyed with written confirmation.
The marketplace we will never build
Life, disability, and long-term care insurance sit outside federal genetic-discrimination protections. We will never broker those products against a member genome. A permanent exclusion, not a deferral.
The quietest page in your Folio
At every draw, a few tubes are set aside for your future self.
Plasma from each baseline draw is aliquoted, frozen, and held under your consent. Most of it is never assayed now, deliberately: assays get better and cheaper every year, but a sample of you at this moment can never be collected later. When a measurement worth running exists in three years, your baseline is already waiting for it, and the result is read against everything else on your page.
Membership
Priced plainly, including the part other companies bury.
Essential is deliberately consultation-free: your Folio is physician-reviewed and delivered asynchronously, and clinician time is bundled where it belongs, in the tiers built around it. We say this on the pricing page rather than in the fine print, because surprise is the enemy of trust.
Once
- Whole genome at 30x
- All seven sections, physician-reviewed
- Plasma banked at your draw
- Medication matching, for life
- Asynchronous review, no visit included
The founding page. Consultations begin at Complete, and we tell you that here, not at checkout.
Once
- Everything in Essential
- NMR metabolomics and clinical chemistry
- One physician consultation
- Family carrier interpretation
The full founding read, with an hour of medicine attached to it.
Per year
- Everything in Complete
- Annual proteomics against your personal ranges
- The annual reinterpretation cycle
- Two consultations per year
- Re-sequencing every two to three years
The tier the record was designed for. Year three is worth more than day one.
From, per year
- Concierge, by application
- Deeper sequencing and expanded molecular panel
- Direct clinical access
- Family Folios
A record kept for a household, not a person.
Folio at Birth
The record opens on day one.
Families bank cord blood against a small chance of future use. A genome read at birth is useful in the first week and every year after: pharmacogenomics on file before the first pediatric prescription, and a founding page the rest of a life accretes on. In addition to state newborn screening, never in place of it.
The clinically superior read is the trio: newborn and both parents together, which is how de novo variants are resolved. We also say the commercial part plainly: one birth opens three Folios.
At eighteen the Folio is offered to its subject. They may take it over, restrict parental access, or delete it entirely. A record that begins before consent must end in consent.
Tranche I
Childhood-actionable findings and pharmacogenomics
Tranche II
Carrier findings, for the parents' family planning
Tranche III
Adult-onset findings
Legacy · For the family of someone gone
A sequence for the living.
The correct genetics is to test the affected person first: a family's exact variant is what makes every relative's testing informative. When that person has died, the sample usually still exists, because hospitals hold pathology specimens for years. There is no clock on this decision.
A Legacy sequence proceeds with the consent of next of kin and, where an estate is involved, its counsel. What comes back is written into the family's records: an exact variant to screen for, or the quiet relief of one ruled out.
Members bank aliquots precisely so their families never need a recovery sequence.
Archived pathology block
The default path. A records request, on no one's deadline.
Banked Folio aliquot
If they were a member who banked, nothing needs recovering.
Near-term collection
Arranged physician to physician when a family asks early.
How a Folio arrives
Through the physician you already trust.
Folio launches inside a small number of concierge and executive-health practices. Your physician introduces it, reads the founding page with you, and writes in its margins for years afterward. The record, the account, and the consent remain yours through Folio, so the Folio follows you: across practices, across cities, across decades.
We also work directly with family offices whose health-advisory function serves the whole household. A family is the natural unit of a genome.
Plain answers